{"product_id":"bimagrumab-bym338-10mg","title":"Bimagrumab (BYM338) 10mg","description":"\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"676\" data-start=\"197\"\u003e\u003cstrong data-end=\"220\" data-start=\"197\"\u003eBimagrumab (BYM338)\u003c\/strong\u003e is a \u003cstrong data-end=\"255\" data-start=\"226\"\u003ehuman monoclonal antibody\u003c\/strong\u003e that binds \u003cstrong data-end=\"318\" data-start=\"267\"\u003eactivin type II receptors (ActRIIA and ActRIIB)\u003c\/strong\u003e, functionally \u003cstrong data-end=\"395\" data-start=\"333\"\u003eblocking signaling from multiple TGF-β–superfamily ligands\u003c\/strong\u003e that use these receptors (notably \u003cstrong data-end=\"449\" data-start=\"430\"\u003emyostatin\/GDF-8\u003c\/strong\u003e and \u003cstrong data-end=\"466\" data-start=\"454\"\u003eactivins\u003c\/strong\u003e). This “receptor blockade” strategy is broader than a pure anti-myostatin antibody and is designed to drive \u003cstrong data-end=\"601\" data-start=\"575\"\u003eincreases in lean mass\u003c\/strong\u003e while also altering adipose biology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"781\" data-start=\"678\"\u003e\u003cstrong data-end=\"700\" data-start=\"678\"\u003eRegulatory status:\u003c\/strong\u003e Investigational; \u003cstrong data-end=\"742\" data-start=\"718\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"1053\" data-start=\"783\"\u003e\u003cstrong data-end=\"815\" data-start=\"783\"\u003eOwnership \/ development arc:\u003c\/strong\u003e Originally developed by \u003cstrong data-end=\"852\" data-start=\"840\"\u003eNovartis\u003c\/strong\u003e for muscle-wasting indications (e.g., inclusion body myositis), later acquired with \u003cstrong data-end=\"949\" data-start=\"937\"\u003eVersanis\u003c\/strong\u003e by \u003cstrong data-end=\"966\" data-start=\"953\"\u003eEli Lilly\u003c\/strong\u003e as part of an obesity\/body-composition strategy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1058\" data-start=\"1055\"\u003e\n\u003ch2 data-end=\"1115\" data-start=\"1060\"\u003e2) Why the ActRII pathway is high-leverage biology\u003c\/h2\u003e\n\u003cp data-end=\"1280\" data-start=\"1116\"\u003eActRIIA\/ActRIIB are key nodes for \u003cstrong data-end=\"1181\" data-start=\"1150\"\u003emyostatin\/activin signaling\u003c\/strong\u003e, which restrains muscle growth and can promote catabolic tone. Blocking ActRII signaling tends to:\u003c\/p\u003e\n\u003cul data-end=\"1473\" data-start=\"1282\"\u003e\n\u003cli data-end=\"1348\" data-start=\"1282\"\u003e\n\u003cp data-end=\"1348\" data-start=\"1284\"\u003e\u003cstrong data-end=\"1308\" data-start=\"1284\"\u003eIncrease muscle mass\u003c\/strong\u003e via reduced SMAD2\/3 signaling in muscle\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1473\" data-start=\"1349\"\u003e\n\u003cp data-end=\"1473\" data-start=\"1351\"\u003eShift “nutrient partitioning” and body composition—\u003cstrong data-end=\"1447\" data-start=\"1402\"\u003efat mass can fall even as lean mass rises\u003c\/strong\u003e in certain human settings\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1717\" data-start=\"1475\"\u003e\u003cstrong data-end=\"1505\" data-start=\"1475\"\u003eCore translational lesson:\u003c\/strong\u003e These agents often produce \u003cstrong data-end=\"1568\" data-start=\"1533\"\u003erobust body-composition changes\u003c\/strong\u003e, but \u003cstrong data-end=\"1597\" data-start=\"1574\"\u003efunctional outcomes\u003c\/strong\u003e(strength, walking performance) can be inconsistent and highly context-dependent. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1722\" data-start=\"1719\"\u003e\n\u003ch2 data-end=\"1799\" data-start=\"1724\"\u003e3) Additional benefits \/ effects under investigation (evidence-weighted)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2849\" data-start=\"1801\"\u003e\n\u003cthead data-end=\"1862\" data-start=\"1801\"\u003e\n\u003ctr data-end=\"1862\" data-start=\"1801\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"1818\" data-start=\"1801\"\u003eBENEFIT DOMAIN\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"1834\" data-start=\"1818\"\u003eKEY TAKEAWAYS\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"1862\" data-start=\"1834\"\u003eBEST SUPPORTING EVIDENCE\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2849\" data-start=\"1877\"\u003e\n\u003ctr data-end=\"2119\" data-start=\"1877\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1939\" data-start=\"1877\"\u003e1) Fat-mass reduction with lean-mass gain (“recomposition”)\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2119\" data-start=\"1939\"\u003eIn adults with \u003cstrong data-end=\"1984\" data-start=\"1956\"\u003eT2D + overweight\/obesity\u003c\/strong\u003e, bimagrumab produced \u003cstrong data-end=\"2029\" data-start=\"2006\"\u003elarge fat-mass loss\u003c\/strong\u003e with \u003cstrong data-end=\"2053\" data-start=\"2035\"\u003elean-mass gain\u003c\/strong\u003e over 48 weeks vs placebo. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2327\" data-start=\"2120\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2161\" data-start=\"2120\"\u003e2) Glycemic and metabolic improvements\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2327\" data-start=\"2161\"\u003eSame Phase 2 study reported improvements in \u003cstrong data-end=\"2252\" data-start=\"2207\"\u003eglycemic control and metabolic parameters\u003c\/strong\u003e alongside body-composition change. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2566\" data-start=\"2328\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2384\" data-start=\"2328\"\u003e3) Sarcopenia \/ mobility signals (selected subgroups)\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2566\" data-start=\"2384\"\u003eIn sarcopenia trials, bimagrumab increased \u003cstrong data-end=\"2455\" data-start=\"2429\"\u003elean mass and strength\u003c\/strong\u003e and improved mobility in those with \u003cstrong data-end=\"2525\" data-start=\"2492\"\u003eslower baseline walking speed\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2849\" data-start=\"2567\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2631\" data-start=\"2567\"\u003e4) “Quality of weight loss” in combination with GLP-1 therapy\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2849\" data-start=\"2631\"\u003eCombination studies (e.g., with semaglutide) have been presented as improving \u003cstrong data-end=\"2761\" data-start=\"2711\"\u003efat loss while preserving\/increasing lean mass\u003c\/strong\u003e; details vary by program and disclosure format. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"3060\" data-start=\"2851\"\u003e\u003cstrong data-end=\"2877\" data-start=\"2851\"\u003eEvidence-quality note:\u003c\/strong\u003e The strongest peer-reviewed efficacy anchor for obesity\/metabolic outcomes is the \u003cstrong data-end=\"2993\" data-start=\"2960\"\u003eJAMA Network Open Phase 2 RCT\u003c\/strong\u003e in T2D + obesity\/overweight. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3065\" data-start=\"3062\"\u003e\n\u003ch2 data-end=\"3102\" data-start=\"3067\"\u003e4) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"3139\" data-start=\"3104\"\u003e4.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3471\" data-start=\"3140\"\u003e\n\u003cli data-end=\"3345\" data-start=\"3140\"\u003e\n\u003cp data-end=\"3345\" data-start=\"3142\"\u003e\u003cstrong data-end=\"3182\" data-start=\"3142\"\u003eBimagrumab binds ActRIIA and ActRIIB\u003c\/strong\u003e, preventing ligand-driven receptor signaling (myostatin\/activins and related ligands that signal through these receptors). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3471\" data-start=\"3346\"\u003e\n\u003cp data-end=\"3471\" data-start=\"3348\"\u003eDownstream effect: reduced \u003cstrong data-end=\"3386\" data-start=\"3375\"\u003eSMAD2\/3\u003c\/strong\u003e transcriptional signaling in muscle, shifting toward anabolism\/hypertrophy programs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3504\" data-start=\"3473\"\u003e4.2 Why fat mass can drop\u003c\/h3\u003e\n\u003cp data-end=\"3898\" data-start=\"3505\"\u003eHuman and translational literature frames ActRII pathway inhibition as influencing \u003cstrong data-end=\"3638\" data-start=\"3588\"\u003eadipose tissue biology and energy partitioning\u003c\/strong\u003e, not just muscle. In the T2D obesity Phase 2 RCT, fat mass fell substantially while lean mass rose—suggesting a systemic repartitioning effect rather than appetite suppression (bimagrumab is not a GLP-1-type anorectic). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3903\" data-start=\"3900\"\u003e\n\u003ch2 data-end=\"3956\" data-start=\"3905\"\u003e5) Pharmacokinetics and dosing (program-level)\u003c\/h2\u003e\n\u003cp data-end=\"4229\" data-start=\"3957\"\u003eAs a monoclonal antibody, bimagrumab exhibits \u003cstrong data-end=\"4021\" data-start=\"4003\"\u003etypical mAb PK\u003c\/strong\u003e (slow clearance relative to peptides, FcRn recycling, limited distribution). In key body-composition trials it was administered \u003cstrong data-end=\"4188\" data-start=\"4150\"\u003eperiodically (e.g., every 4 weeks)\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"4234\" data-start=\"4231\"\u003e\n\u003ch2 data-end=\"4279\" data-start=\"4236\"\u003e6) Clinical evidence (high-yield trials)\u003c\/h2\u003e\n\u003ch3 data-end=\"4369\" data-start=\"4281\"\u003e6.1 T2D + overweight\/obesity (48-week Phase 2 RCT; body composition primary focus)\u003c\/h3\u003e\n\u003cp data-end=\"4500\" data-start=\"4370\"\u003eIn a randomized Phase 2 trial in adults with \u003cstrong data-end=\"4457\" data-start=\"4415\"\u003etype 2 diabetes and obesity\/overweight\u003c\/strong\u003e, ActRII blockade with bimagrumab led to:\u003c\/p\u003e\n\u003cul data-end=\"4649\" data-start=\"4501\"\u003e\n\u003cli data-end=\"4535\" data-start=\"4501\"\u003e\n\u003cp data-end=\"4535\" data-start=\"4503\"\u003e\u003cstrong data-end=\"4532\" data-start=\"4503\"\u003esignificant fat-mass loss\u003c\/strong\u003e,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4563\" data-start=\"4536\"\u003e\n\u003cp data-end=\"4563\" data-start=\"4538\"\u003e\u003cstrong data-end=\"4556\" data-start=\"4538\"\u003elean-mass gain\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4649\" data-start=\"4564\"\u003e\n\u003cp data-end=\"4649\" data-start=\"4566\"\u003e\u003cstrong data-end=\"4592\" data-start=\"4566\"\u003emetabolic improvements\u003c\/strong\u003e over 48 weeks. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4755\" data-start=\"4651\"\u003eThis study is a major reason bimagrumab became interesting for “\u003cstrong data-end=\"4741\" data-start=\"4715\"\u003equality of weight loss\u003c\/strong\u003e” discussions.\u003c\/p\u003e\n\u003ch3 data-end=\"4791\" data-start=\"4757\"\u003e6.2 Sarcopenia (16-week RCT)\u003c\/h3\u003e\n\u003cp data-end=\"5045\" data-start=\"4792\"\u003eA randomized trial reported that bimagrumab treatment over 16 weeks increased \u003cstrong data-end=\"4898\" data-start=\"4870\"\u003emuscle mass and strength\u003c\/strong\u003e in older adults with sarcopenia and improved mobility particularly in those with \u003cstrong data-end=\"5002\" data-start=\"4980\"\u003eslow walking speed\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5132\" data-start=\"5047\"\u003e6.3 Inclusion body myositis (sIBM): long-term safety without functional benefit\u003c\/h3\u003e\n\u003cp data-end=\"5408\" data-start=\"5133\"\u003eLong-term evaluation in \u003cstrong data-end=\"5165\" data-start=\"5157\"\u003esIBM\u003c\/strong\u003e reported that bimagrumab was \u003cstrong data-end=\"5222\" data-start=\"5195\"\u003esafe and well tolerated\u003c\/strong\u003e but \u003cstrong data-end=\"5278\" data-start=\"5227\"\u003edid not produce significant functional benefits\u003c\/strong\u003e—a classic example of the “mass ≠ function” challenge in advanced neuromuscular disease. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"5413\" data-start=\"5410\"\u003e\n\u003ch2 data-end=\"5469\" data-start=\"5415\"\u003e7) Safety and tolerability (what’s most defensible)\u003c\/h2\u003e\n\u003ch3 data-end=\"5510\" data-start=\"5471\"\u003e7.1 Common \/ program-relevant AEs\u003c\/h3\u003e\n\u003cp data-end=\"5751\" data-start=\"5511\"\u003eAcross trials, bimagrumab has been described as generally \u003cstrong data-end=\"5587\" data-start=\"5569\"\u003ewell tolerated\u003c\/strong\u003e, with \u003cstrong data-end=\"5631\" data-start=\"5594\"\u003einjection\/infusion-site reactions\u003c\/strong\u003e reported in some settings and expected mAb-class tolerability considerations. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5798\" data-start=\"5753\"\u003e7.2 Mechanism-informed risks to monitor\u003c\/h3\u003e\n\u003cp data-end=\"5923\" data-start=\"5799\"\u003eBecause ActRII blockade is broader than selective anti-myostatin, there are theoretical and program-observed considerations:\u003c\/p\u003e\n\u003cul data-end=\"6313\" data-start=\"5924\"\u003e\n\u003cli data-end=\"6069\" data-start=\"5924\"\u003e\n\u003cp data-end=\"6069\" data-start=\"5926\"\u003e\u003cstrong data-end=\"5991\" data-start=\"5926\"\u003eDiscrepancy between lean mass gain and functional performance\u003c\/strong\u003e (especially without training\/rehab) \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6196\" data-start=\"6070\"\u003e\n\u003cp data-end=\"6196\" data-start=\"6072\"\u003ePotential \u003cstrong data-end=\"6124\" data-start=\"6082\"\u003efluid shifts or tissue quality changes\u003c\/strong\u003e (needs endpoint-specific study; not reliably inferred from DXA alone)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6313\" data-start=\"6197\"\u003e\n\u003cp data-end=\"6313\" data-start=\"6199\"\u003eIn vulnerable populations, muscle hypertrophy without parallel neuromotor adaptation could be functionally neutral\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6318\" data-start=\"6315\"\u003e\n\u003ch2 data-end=\"6384\" data-start=\"6320\"\u003e8) Regulatory and development landscape (recent, practical)\u003c\/h2\u003e\n\u003cul data-end=\"6789\" data-start=\"6385\"\u003e\n\u003cli data-end=\"6521\" data-start=\"6385\"\u003e\n\u003cp data-end=\"6521\" data-start=\"6387\"\u003e\u003cstrong data-end=\"6414\" data-start=\"6387\"\u003eLilly acquired Versanis\u003c\/strong\u003e (bimagrumab) to strengthen its cardiometabolic\/obesity pipeline. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6789\" data-start=\"6522\"\u003e\n\u003cp data-end=\"6789\" data-start=\"6524\"\u003eLilly later \u003cstrong data-end=\"6584\" data-start=\"6536\"\u003ehalted at least one bimagrumab obesity trial\u003c\/strong\u003e for “strategic business reasons,” while other studies have continued—illustrating that its clinical trajectory is shaped by portfolio strategy as well as biology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6794\" data-start=\"6791\"\u003e\n\u003ch2 data-end=\"6840\" data-start=\"6796\"\u003e9) Comparative positioning (quick matrix)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7628\" data-start=\"6842\"\u003e\n\u003cthead data-end=\"6941\" data-start=\"6842\"\u003e\n\u003ctr data-end=\"6941\" data-start=\"6842\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6852\" data-start=\"6842\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"6886\" data-start=\"6852\"\u003eBimagrumab (ActRIIA\/B blockade)\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"6941\" data-start=\"6886\"\u003eAnti-myostatin mAbs (e.g., “pure” GDF-8 antibodies)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7628\" data-start=\"6956\"\u003e\n\u003ctr data-end=\"7109\" data-start=\"6956\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6978\" data-start=\"6956\"\u003eBreadth of blockade\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7076\" data-start=\"6978\"\u003e\n\u003cstrong data-end=\"6991\" data-start=\"6980\"\u003eBroader\u003c\/strong\u003e (myostatin + activins\/other ActRII ligands) \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7109\" data-start=\"7076\"\u003eNarrower (myostatin-specific)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7291\" data-start=\"7110\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7129\" data-start=\"7110\"\u003eBody composition\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7241\" data-start=\"7129\"\u003eOften \u003cstrong data-end=\"7147\" data-start=\"7137\"\u003elean ↑\u003c\/strong\u003e and \u003cstrong data-end=\"7161\" data-start=\"7152\"\u003efat ↓\u003c\/strong\u003e (not just lean ↑) in some human trials \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7291\" data-start=\"7241\"\u003eMore consistently lean ↑; fat effects variable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7460\" data-start=\"7292\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7314\" data-start=\"7292\"\u003eFunctional outcomes\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7414\" data-start=\"7314\"\u003eMixed; context-dependent; often limited in severe disease \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7460\" data-start=\"7414\"\u003eAlso mixed; “mass ≠ function” still common\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7628\" data-start=\"7461\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7479\" data-start=\"7461\"\u003e“GLP-1 era” fit\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7577\" data-start=\"7479\"\u003eMuscle-sparing \/ quality-of-weight-loss adjunct concept \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7628\" data-start=\"7577\"\u003eSimilar concept being pursued with other agents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7633\" data-start=\"7630\"\u003e\n\u003ch2 data-end=\"7699\" data-start=\"7635\"\u003e10) Future directions (what would make it succeed clinically)\u003c\/h2\u003e\n\u003cp data-end=\"7798\" data-start=\"7700\"\u003eIf ActRII blockade is to become a mainstream metabolic therapy concept, success likely depends on:\u003c\/p\u003e\n\u003col data-end=\"8394\" data-start=\"7800\"\u003e\n\u003cli data-end=\"7947\" data-start=\"7800\"\u003e\n\u003cp data-end=\"7947\" data-start=\"7803\"\u003e\u003cstrong data-end=\"7831\" data-start=\"7803\"\u003eFunction-first endpoints\u003c\/strong\u003e, not DXA-first\u003cbr data-end=\"7849\" data-start=\"7846\"\u003ePower, stair climb, VO₂peak, falls, frailty indices—paired with structured resistance training.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8079\" data-start=\"7949\"\u003e\n\u003cp data-end=\"8079\" data-start=\"7952\"\u003e\u003cstrong data-end=\"7978\" data-start=\"7952\"\u003eMuscle quality metrics\u003c\/strong\u003e\u003cbr data-end=\"7981\" data-start=\"7978\"\u003eMRI muscle volume, intramuscular fat, strength per cross-sectional area, and gait biomechanics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8394\" data-start=\"8081\"\u003e\n\u003cp data-end=\"8394\" data-start=\"8084\"\u003e\u003cstrong data-end=\"8120\" data-start=\"8084\"\u003eCombination logic with incretins\u003c\/strong\u003e\u003cbr data-end=\"8123\" data-start=\"8120\"\u003eClear demonstration that adding bimagrumab to GLP-1\/GIP therapy improves \u003cem data-end=\"8222\" data-start=\"8199\"\u003eclinically meaningful\u003c\/em\u003e outcomes (mobility, maintenance of resting energy expenditure, durability of weight maintenance), not just body-composition ratios\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684838306130,"sku":null,"price":7250.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Bimagrumab_10mg.png?v=1770834786","url":"https:\/\/sciencepeptideslab.com\/products\/bimagrumab-bym338-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}